日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

鲁索替尼单药治疗与联合干扰素治疗骨髓纤维化患者的疗效比较

Erdos, Katie; Alshareef, Aya; Silver, Richard T; Scandura, Joseph M; Abu-Zeinah, Ghaith

Are thrombosis, progression, and survival in ET predictable?

ET患者的血栓形成、病情进展和生存情况是否可以预测?

Abu-Zeinah, Ghaith; Erdos, Katie; Lee, Neville; Lebbe, Ahamed; Bouhali, Imane; Khalid, Mohammed; Silver, Richard T; Scandura, Joseph M

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis

一项随机、双盲、安慰剂对照的3期研究,旨在评估ropeginterferon alfa-2b治疗早期/低危原发性骨髓纤维化患者的疗效和安全性。

Abu-Zeinah, Ghaith; Qin, Albert; Gill, Harinder; Komatsu, Norio; Mascarenhas, John; Shih, Weichung Joe; Zagrijtschuk, Oleh; Sato, Toshiaki; Shimoda, Kazuya; Silver, Richard T; Mesa, Ruben

Incidence of blast phase in myelofibrosis according to anemia severity

根据贫血严重程度划分的骨髓纤维化急变期发生率

Mora, Barbara; Maffioli, Margherita; Rumi, Elisa; Guglielmelli, Paola; Caramella, Marianna; Kuykendall, Andrew; Palandri, Francesca; Iurlo, Alessandra; De Stefano, Valerio; Kiladjian, Jean-Jacques; Elli, Elena M; Polverelli, Nicola; Gotlib, Jason; Albano, Francesco; Silver, Richard T; Benevolo, Giulia; Ross, David M; Devos, Timothy; Borsani, Oscar; Barbui, Tiziano; Porta, Matteo G Della; Bertù, Lorenza; Komrokji, Rami; Vannucchi, Alessandro M; Passamonti, Francesco

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

一项随机3期临床试验,比较干扰素-α与羟基脲治疗真性红细胞增多症和原发性血小板增多症的疗效。

Mascarenhas, John; Kosiorek, Heidi E; Prchal, Josef T; Rambaldi, Alessandro; Berenzon, Dmitriy; Yacoub, Abdulraheem; Harrison, Claire N; McMullin, Mary Frances; Vannucchi, Alessandro M; Ewing, Joanne; O'Connell, Casey L; Kiladjian, Jean-Jacques; Mead, Adam J; Winton, Elliott F; Leibowitz, David S; De Stefano, Valerio; Arcasoy, Murat O; Kessler, Craig M; Catchatourian, Rosalind; Rondelli, Damiano; Silver, Richard T; Bacigalupo, Andrea; Nagler, Arnon; Kremyanskaya, Marina; Levine, Max F; Arango Ossa, Juan E; McGovern, Erin; Sandy, Lonette; Salama, Mohamad E; Najfeld, Vesna; Tripodi, Joseph; Farnoud, Noushin; Penson, Alexander V; Weinberg, Rona Singer; Price, Leah; Goldberg, Judith D; Barbui, Tiziano; Marchioli, Roberto; Tognoni, Gianni; Rampal, Raajit K; Mesa, Ruben A; Dueck, Amylou C; Hoffman, Ronald

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后,患者和医生报告的疼痛情况

Flynn, Kathryn E; Atallah, Ehab; Lin, Li; Shah, Neil P; Silver, Richard T; Larson, Richard A; Panilla-Ibarz, Javier; Thompson, James E; Oehler, Vivian G; Radich, Jerald P; Kota, Vamsi; Mauro, Michael J; Schiffer, Charles A; Cortes, Jorge; Weinfurt, Kevin P

Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors

慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的患者自述功能结局

Schoenbeck, Kelly L; Atallah, Ehab; Lin, Li; Weinfurt, Kevin P; Cortes, Jorge; Deininger, Michael W N; Kota, Vamsi; Larson, Richard A; Mauro, Michael J; Oehler, Vivian G; Pinilla-Ibarz, Javier; Radich, Jerald P; Schiffer, Charles A; Shah, Neil P; Silver, Richard T; Thompson, James E; Flynn, Kathryn E

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后疗效评估:一项非随机临床试验

Atallah, Ehab; Schiffer, Charles A; Radich, Jerald P; Weinfurt, Kevin P; Zhang, Mei-Jie; Pinilla-Ibarz, Javier; Kota, Vamsi; Larson, Richard A; Moore, Joseph O; Mauro, Michael J; Deininger, Michael W N; Thompson, James E; Oehler, Vivian G; Wadleigh, Martha; Shah, Neil P; Ritchie, Ellen K; Silver, Richard T; Cortes, Jorge; Lin, Li; Visotcky, Alexis; Baim, Arielle; Harrell, Jill; Helton, Bret; Horowitz, Mary; Flynn, Kathryn E

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Fedratinib 可改善既往接受过 Ruxolitinib 治疗的骨髓纤维化患者的骨髓纤维化相关症状和健康相关生活质量:来自 II 期 JAKARTA2 试验的患者报告结果

Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Jourdan, Eric; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Tang, Derek; Abraham, Pranav; Lord-Bessen, Jennifer; Rose, Shelonitda; Guo, Shien; Liao, Weiqin; Mesa, Ruben A

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

干扰素-α2和炎症在治疗费城染色体阴性慢性骨髓增生性肿瘤中的新视角

Hasselbalch, Hans C; Silver, Richard T